Background Prevalence of ischemic stroke in young adults is increasing worldwide. Risk factors of stroke in young women and men are diverse. Women and men may have differences cardiovascular disease (CVD) risk factors, which related to recurrent stroke and major adverse cardiovascular events. Determine sex differences in risk for developing recurrent stroke may help us improving secondary prevention protocols. Purpose We examined whether young ischemic stroke women and men had differences risk for developing recurrent stroke. Methods We analyzed data from the five-year stroke registry of a tertiary care, teaching, and referral hospital in the South of Thailand. There were 3,135 ischemic strokes admitted during October 2011 and February 2016, which 583 (18.6%) of young adults aged 16-50 years old. Approximately one-third was women (35.2%). Risk for recurrent stroke was identified based on the Essen Stroke Risk Score (ESRS). ESRS score ranged from 0 to 9, the higher the score indicated the higher risk for recurrent stroke. Two risk levels were identified as low (score 0-2), and high (score 3-9). Mann-Whitney U test, Chi-square, and univariate estimates of odds ratio (95%CI) were calculated to compare sex differences. Results Most common CVD risks in women were hypertension (49.8%), and diabetes (22.0%), whereas smoking (83.6%), alcohol drinking (78.6%), and hypertension (41.0%) were more common in men. Compared to men, women had lower total score on ESRS (U=7.58, p=0.000). They had higher score on the index of hypertension (U=2.03, p=0.042), but less score on smoking (U=17.11, p=0.000). There were a less number of women than did men in the high risk level for recurrent (2.4 vs 16.7%; Chi = 26.11;). An increment odds ratio of hypertension (OR 1.25, 95%CI 1.01-1.56), and previous myocardial infarction (OR 3.12, 95%CI 2.59-3.75) were found in women compared to men. In contrast, men had increment odds ratio of smoking (OR 3.72,, and alcohol drinking (OR 3.12, 95%CI 2.59-3.75). Conclusions Young stroke women and men had differences risks levels and risk factors for developing recurrent stroke. Although women had fewer score and lower level for recurrent, they had higher risk in hypertension and myocardial infarction. Higher risk in men was mainly attributed by smoking. Hence, secondary prevention to reduce recurrent event should be considering to these sex differences. Funding Acknowledgements: Topic: Cardiovascular Disease in Special Populations -Other Background: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis and increased risk of morbidity and mortality from cardiovascular disease (CVD) as compared to age and gender-matched controls due to the high prevalence of traditional CVD risk factors (tCVD-RF) and systemic inflammation. EULAR(European League Against Rheumatism) recommends annual cardiovascular risk assessment (CRA) for patients with RA. The 2016 ESC guidelines on CVD prevention in clinical practice recommended a systematic CVD assessment as a screening tool in targeted high-risk subpopulation such as RA, using the SCORE system that gives an estimate of the 10-year risk of a first fatal atherosclerotic event.
Funding Acknowledgements: Topic: Peripheral Vascular and Cerebrovascular Disease -Other Background Prevalence of ischemic stroke in young adults is increasing worldwide. Risk factors of stroke in young women and men are diverse. Women and men may have differences cardiovascular disease (CVD) risk factors, which related to recurrent stroke and major adverse cardiovascular events. Determine sex differences in risk for developing recurrent stroke may help us improving secondary prevention protocols. Purpose We examined whether young ischemic stroke women and men had differences risk for developing recurrent stroke. Methods We analyzed data from the five-year stroke registry of a tertiary care, teaching, and referral hospital in the South of Thailand. There were 3,135 ischemic strokes admitted during October 2011 and February 2016, which 583 (18.6%) of young adults aged 16-50 years old. Approximately one-third was women (35.2%). Risk for recurrent stroke was identified based on the Essen Stroke Risk Score (ESRS). ESRS score ranged from 0 to 9, the higher the score indicated the higher risk for recurrent stroke. Two risk levels were identified as low (score 0-2), and high (score 3-9). Mann-Whitney U test, Chi-square, and univariate estimates of odds ratio (95%CI) were calculated to compare sex differences. Results Most common CVD risks in women were hypertension (49.8%), and diabetes (22.0%), whereas smoking (83.6%), alcohol drinking (78.6%), and hypertension (41.0%) were more common in men. Compared to men, women had lower total score on ESRS (U=7.58, p=0.000). They had higher score on the index of hypertension (U=2.03, p=0.042), but less score on smoking (U=17.11, p=0.000). There were a less number of women than did men in the high risk level for recurrent (2.4 vs 16.7%; Chi = 26.11; ). An increment odds ratio of hypertension (OR 1.25, 95%CI 1.01-1.56), and previous myocardial infarction (OR 3.12, 95%CI 2.59-3.75) were found in women compared to men. In contrast, men had increment odds ratio of smoking (OR 3.72, , and alcohol drinking (OR 3.12, 95%CI 2.59-3.75). Conclusions Young stroke women and men had differences risks levels and risk factors for developing recurrent stroke. Although women had fewer score and lower level for recurrent, they had higher risk in hypertension and myocardial infarction. Higher risk in men was mainly attributed by smoking. Hence, secondary prevention to reduce recurrent event should be considering to these sex differences. Funding Acknowledgements: Topic: Cardiovascular Disease in Special Populations -Other Background: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis and increased risk of morbidity and mortality from cardiovascular disease (CVD) as compared to age and gender-matched controls due to the high prevalence of traditional CVD risk factors (tCVD-RF) and systemic inflammation. EULAR(European League Against Rheumatism) recommends annual cardiovascular risk assessment (CRA) for patients with RA. The 2016 ESC guidelines on CVD prevention in clinical practice recommended a systematic CVD assessment as a screening tool in targeted high-risk subpopulation such as RA, using the SCORE system that gives an estimate of the 10-year risk of a first fatal atherosclerotic event.
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Objective: Three-fold re-audit aims: 1.to determine the prevalence of the tCVD-RF (diabetes, hypertension, hyperlipidemia, long term corticosteroid use and smoking) in RA patients 2.to assess management of CVD risk in RA patients in comparison to the EULAR recommendations and ESC guidelines 3.to identify RA disease activity control Method: This study involved 2-teaching hospitals in Mid-West region of Ireland. 100 RA patients were recruited between May-June 2016 and January-February 2017 in each audit and reaudit phases respectively. Demographic data, disease duration and activity, Rheumatoid Factor/ACPA status, concomitant ESR and CRP, DAS28, tCVD-RFs, past history of ischemic heart disease (IHD), related co-morbidities (TIA, CVA, PVD, aortic aneurysm) and drug history (current RA, anti-hypertensive and lipid lowering medications) was noted.Data on blood pressure (BP), lipid profile and blood glucose (random, fasting or HbA1c) were sought in the preceding 4-years, and if treatment were commenced as per the guidelines. The 10-year risk of fatal CVD was calculated using the Systematic COronary Risk Evaluation (SCORE) chart: total cholesterol/HDL ratio was used as measure of lipid profile and risk was multiplied by 1.5 if patient had 2 of these 3 criteria: disease duration of >10 years, positive RF/ACPA, presence of severe extra-articular manifestations. Result: Overall results are summarized in Figure. There was improvement in the efficiency of Abstract No: 301.
recording tCVD-RFs i.e. BMI, smoking, hypertension by 66%, 7% and 4% respectively and better management of hypertension by 9%. 8% patients received smoking cessation advice versus none before. Blood glucose and lipid profiles were well monitored but reduced by 8% and 7% respectively. RA disease activity was adequately controlled and approximately 60% patients were in remission in both audits. Due to the lack of required data, only 43 patients had their 10-year CVD risk SCORE model calculated. There was 12% reduction in the moderate risk group to develop fatal CVD within 10-years. Conclusion: CVD risk management although improved, still remains suboptimal and requires ongoing surveillance. Rheumatologists should actively participate in annual CRA in RA patients to reduce the incidence of IHD. Aim: The aim of the study is twofold: To determine the efficiency of screening for hyperlipidemia in our RA cohort and secondly, to evaluate the initiation and optimization of lipid lowering therapy among the indicated RA patients after devising departmental guidelines and continuous education based on the initial results of first audit in June 2016. Methods: This multicenter re-audit involved 2 teaching hospitals (Croom hospital & University Hospital Limerick). 100 consecutive patients with definite RA were recruited in January-February 2017. A proforma was completed for each patient based on medical notes and electronic record. In those patients where data on age, gender, smoking, blood pressure and lipid profile were complete, the 10-year risk of fatal CVD was calculated by using the SCORE chart. The patients were stratified into 4 risk categories, and together with measurement of target LDL-cholesterol (LDL-c) levels, recommendations for lipid lowering measures were adapted: Ideal LDL-c for low (SCORE <1%) and moderate risk patients (SCORE !1-<5%) should be <3.0 mmol/L, <2.6mmol/L for high risk (SCORE !5-<10%) & <1.8mmol/ L for very high risk patients (SCORE !10%). Statins were the recommended treatment. Results: Among the 100 patients, full lipid profile was performed in 80% patients within the last 4-years as compared to 87% patients in first audit. In both studies 43% patients had adequate data to calculate the 10-year risk of fatal CVD. Figure-1 illustrates 10-year CVD risk based on SCORE model stratifying patients in 4 risk categories on the basis of target LDL-c and also compares patients in these categories in both audits. We found that overall there was 5% improvement in lipidaemic control indicating optimized statin dose and 14% patients achieved their target LDL-c while on treatment. Overall 41% patients (18/43) had an indication for de novo statin therapy in both audits as they were not on treatment despite fulfilling the above-mentioned criteria. Conclusion: Despite sufficiently having adequate indication to be on lipid lowering therapy, majority of the patients remained untreated. To address this issue, we recommend further education both at departmental and community level and annual screening using the latest Joint ESC guidelines of the 10-year risk of fatal CVD in combination with target LDL-c measurement, with re-audit to see if this is achieved. Methods: The data on deaths from cardiovascular disease (ICD-10 codes I00-I99), cerebrovascular diseases (ICD-10 codes I60-I69), and ischemic heart disease (ICD-10 codes I20-I25), by age group and gender, were obtained from the annual report of the Croatian Bureau of Statistics. We calculated the age-specific mortality rates using the revised mid-year population estimates, and rates were standardized using the European Standard Population (1976). We used Joinpoint Regression analysis to describe trends in mortality, with a maximum of 2 joinpoints and a Monte Carlo simulation to calculate p-values for a series of permutation tests. We applied the joinpoint analysis to the age standardized rates and their respective standard errors, for each diagnosis group and each sex separately.
Results: Standardized mortality rates (ASR-E) for cardiovascular diseases in the 2001-2016 period decreased from 581.6 to 355.3/100,000 in men, and from 409 to 239.1/100,000 in women. Joinpoint analysis showed an APC (annual percent change) of -3.4% in men (CI=-3.5 to -3.2), and -3.5% (CI=-3.6 to -3.4) in women. Cerebrovascular diseases mortality also decreased in the same period; in men standardized mortality rate decreased from 170.3 to 93.4/100,000, and in women from 130.2 to 70.5/100.000. Cerebrovascular diseases mortality showed an APC of -3.7% in men (CI=-3.8 to -3.6), and -3.9% (CI=-3.8 to -4.0) in women. Ischemic heart disease mortality showed the smallest, but still significant decrease in both men and women. Standardized mortality rate decreased from 212.7 to 171.9/100,000 in men, and joinpoint analysis showed an APC of -1.4% (CI=-1.6 to -1.2). In women, standardized mortality rate decreased from 123.8 to 101/100,000, with an APC of -1.1% (CI=-1.3 to -0.8).
Conclusion: Trends of mortality rates from cardiovascular diseases in Croatia show a continuous decrease, and this decrease is larger when we look at cardiovascular diseases as a whole, and cerebrovascular disease, and smaller in ischemic heart disease. Mortality rates for cardiovascular diseases and cerebrovascular disease are falling more rapidly in women than in men, while the decreasing trend in mortality rates for ischemic heart disease is more pronounced in men then in women. Despite this decrease, cardiovascular diseases mortality in Croatia remains above the EU average, and therefore it is necessary to further increase preventive measures and improve treatment. Funding Acknowledgements: None Topic: Secondary Prevention Background: High levels of serum uric acid have been associated with adverse outcomes in cardiovascular diseases such as myocardial infarction and heart failure.Purpose: The aim of the current study was to evaluate the prognostic role of serum uric acid levels in patients undergoing cardiac rehabilitation after myocardial revascularization and/or cardiac valve surgery.Methods: The study included 1440 patients with available serum uric acid levels, prospectively followed for 50 AE 17 months. Mean age was 67 AE 11 years; 781 patients (54%) underwent myocardial revascularization, 474 (33%) cardiac valve surgery and 185 (13%) valve-plus-coronary artery by-pass graft surgery. The primary endpoints were overall and cardiovascular mortality while secondary end-points were combined major adverse cardiac and cerebrovascular events.Results: Serum uric acid level mean values were 286 AE 95 mmol/l and elevated serum uric acid levels (!360 mmol/l or 6 mg/dl) were found in 275 patients (19%). Overall mortality (hazard ratio = 2.3; 95% confidence interval: 1.63.2; p < 0.001 -central figure), cardiovascular mortality (hazard ratio = 2.0; 95% confidence interval: 1.23.2; p = 0.004) and major adverse cardiac and cerebrovascular events rate (hazard ratio = 1.5; 95% confidence interval: 1.02.0; p = 0.019) were significantly higher in patients with elevated serum uric acid levels, even after adjustment for age, gender, arterial hypertension, diabetes, glomerular filtration rate, atrial fibrillation and medical therapy. Moreover, strong positive correlations between serum uric acid level and probability of overall mortality (p < 0.001), cardiovascular mortality (p < 0.001) and major adverse cardiac and cerebrovascular events (p = 0.003) were found.Conclusions: Serum uric acid levels predict mortality and adverse cardiovascular outcome in patients undergoing myocardial revascularization and/or cardiac valve surgery even after the adjustment for age, gender, arterial hypertension, diabetes, glomerular filtration rate and medical therapy. Laboratory for sport cardiology "Vita Maxima", Belgrade, Serbia
Funding Acknowledgements: Topic: Obesity Background and Aims: Morbid obesity is a common cause of impaired functional capacity due to development of diastolic dysfunction/heart failure which is one of the main predictors of morbidity and mortality. Therefore, weight loss can be efficient in its improvement. Resting echo as well as cardiopulmonary exercise testing (CPX), as a single test are not able to detect accurately the changes in diastolic function. However, combined exercise stress echo CPX (ESE-CPX) is proposed as noninvasive gold standard for assessment of diastolic function. Objective: To assess the value of combined ESE-CPX in assessment of diastolic function in morbidly obese patients treated with bariatric surgery. Methods: From of data base of 300 pts, we studied 50 pts (74% female, age 39.2AE9.9 years) who all underwent bariatric surgery (laparoscopic gastric bypass) and combined ESE-CPX. Tests were performed before and at follow-up 6 months after surgery. Systolic function (SF) was assessed by 2D echo using biplane Simpson's method. Diastolic function was assessed according to standard guidelines. Measurements have been performed at baseline, before Abstract No: 307.
